Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;106 Suppl 1(Suppl 1):179-92.
doi: 10.1590/s0074-02762011000900023.

Platform for Plasmodium vivax vaccine discovery and development

Sócrates Herrera Valencia  1 , Diana Carolina Rodríguez, Diana Lucía Acero, Vanessa Ocampo, Myriam Arévalo-Herrera
Affiliations
Review

Platform for Plasmodium vivax vaccine discovery and development

Sócrates Herrera Valencia et al. Mem Inst Oswaldo Cruz. 2011 Aug.

Abstract

Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80-100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development.

PubMed Disclaimer

Figures

Figure
Figure
Plasmodium vivax vaccines pipeline.
See this image and copyright information in PMC

References

    1. Acharya P, Pallavi R, Chandran S, Chakravarti H, Middha S, Acharya J, Kochar S, Kochar D, Subudhi A, Boopathi AP, Garg S, Das A, Tatu U. A glimpse into the clinical proteome of human malaria parasites Plasmodium falciparum and Plasmodium vivax. Proteomics Clin Appl. 2009;3:1314–1325. - PubMed
    1. Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL. Four year im-munogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine. 2011 - PubMed
    1. Alonso L, Brown G, Arévalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine M, Mendis K, Newman R, Plowe C, Rodríguez M, Sinden R, Slutsker L, Tanner M. A research agenda to underpin malaria eradication. PLoS Medicine. 2011;8:e1000406. - PMC - PubMed
    1. Alves FA, Souza MT, Goncalves EC, Schneider MP, Marinho AM, Muniz JA, Fragoso SP, Krieger MA, Goldenberg S, Daniel-Ribeiro CT, Carvalho LJ. DNA sequencing of 13 cytokine gene fragments of Aotus infulatus and Saimiri sciureus, two non-human primate models for malaria. Cytokine. 2010;52:151–155. - PubMed
    1. Alves FP, Gil LH, Marrelli MT, Ribolla PE, Camargo EP, Da Silva LH. Asymptomatic carriers of Plasmodium spp as infection source for malaria vector mosquitoes in the Brazilian Amazon. J Med Entomol. 2005;42:777–779. - PubMed

Publication types

Substances